Mutual of America Capital Management LLC Has $7.18 Million Stock Position in Vericel Co. (NASDAQ:VCEL)

Mutual of America Capital Management LLC lowered its holdings in shares of Vericel Co. (NASDAQ:VCEL) by 5.1% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 137,984 shares of the biotechnology company’s stock after selling 7,464 shares during the period. Mutual of America Capital Management LLC owned approximately 0.29% of Vericel worth $7,178,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Knights of Columbus Asset Advisors LLC grew its stake in Vericel by 98.5% in the fourth quarter. Knights of Columbus Asset Advisors LLC now owns 226,015 shares of the biotechnology company’s stock valued at $8,048,000 after acquiring an additional 112,169 shares during the period. Federated Hermes Inc. grew its stake in Vericel by 21.2% in the fourth quarter. Federated Hermes Inc. now owns 560,419 shares of the biotechnology company’s stock valued at $19,957,000 after acquiring an additional 97,952 shares during the period. Geneva Capital Management LLC grew its stake in Vericel by 8.7% in the fourth quarter. Geneva Capital Management LLC now owns 472,963 shares of the biotechnology company’s stock valued at $16,842,000 after acquiring an additional 37,784 shares during the period. Congress Asset Management Co. MA grew its stake in Vericel by 509.1% in the first quarter. Congress Asset Management Co. MA now owns 836,481 shares of the biotechnology company’s stock valued at $43,514,000 after acquiring an additional 699,147 shares during the period. Finally, Congress Wealth Management LLC DE acquired a new stake in Vericel in the first quarter valued at approximately $5,496,000.

Vericel Price Performance

VCEL traded up $0.26 during midday trading on Monday, reaching $46.94. 373,030 shares of the company’s stock traded hands, compared to its average volume of 482,632. The firm has a fifty day moving average of $46.53 and a two-hundred day moving average of $45.05. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -4,694.00 and a beta of 1.70. Vericel Co. has a 52 week low of $30.18 and a 52 week high of $53.05.

Vericel (NASDAQ:VCEL) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Vericel had a return on equity of 0.21% and a net margin of 0.22%. The business had revenue of $51.28 million during the quarter, compared to analyst estimates of $49.07 million. During the same quarter in the prior year, the company posted ($0.16) EPS. Vericel’s quarterly revenue was up 25.0% compared to the same quarter last year. Sell-side analysts forecast that Vericel Co. will post 0.11 EPS for the current year.

Wall Street Analyst Weigh In

VCEL has been the topic of several analyst reports. TD Cowen assumed coverage on Vericel in a research report on Thursday, June 20th. They set a “buy” rating and a $55.00 target price on the stock. HC Wainwright lifted their price target on Vericel from $53.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, May 9th. Truist Financial reiterated a “buy” rating and set a $54.00 price target on shares of Vericel in a report on Tuesday, March 26th. Finally, StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Friday, June 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.17.

Insider Buying and Selling

In other Vericel news, insider Sean C. Flynn sold 6,772 shares of the stock in a transaction on Friday, June 21st. The stock was sold at an average price of $45.02, for a total transaction of $304,875.44. Following the sale, the insider now directly owns 487 shares in the company, valued at approximately $21,924.74. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, insider Sean C. Flynn sold 6,772 shares of the firm’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of $45.02, for a total value of $304,875.44. Following the transaction, the insider now directly owns 487 shares in the company, valued at approximately $21,924.74. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Sean C. Flynn sold 1,474 shares of the firm’s stock in a transaction on Monday, June 24th. The stock was sold at an average price of $45.84, for a total value of $67,568.16. Following the completion of the transaction, the insider now owns 487 shares in the company, valued at $22,324.08. The disclosure for this sale can be found here. Insiders have sold 43,246 shares of company stock worth $1,924,869 in the last 90 days. Insiders own 7.20% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.